
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>ASGE consensus recommendations on the endoscopic management of eosinophilic esophagitis – part 2: disease assessment, monitoring, and pediatric considerations  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>ASGE consensus recommendations on the endoscopic management of eosinophilic esophagitis – part 2: disease assessment, monitoring, and pediatric considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastrointest Endosc 2025 (Vol ■, No. ■)  </li>
<li style="margin-left: 0px;">Topic: Eosinophilic Esophagitis (EoE) – endoscopic approach, pediatric issues, disease assessment &amp; monitoring  </li>
<li style="margin-left: 0px;">Author(s): Evan S. Dellon MD MPH <em>et al.</em>  </li>
</ul>
<details><summary><strong>1. Introduction &amp; Rationale  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">EGD essential for diagnosing suspected EoE, assessing endoscopic findings, obtaining biopsies, performing dilation.  </li>
<li style="margin-left: 0px;">Prior ASGE consensus covered diagnosis, grading (EREFS), and dilation; one monitoring statement lacked agreement.  </li>
<li style="margin-left: 0px;">New Delphi focused on pediatric considerations, disease assessment, monitoring → 28 statements with ≥80 % expert agreement.  </li>
</ul>
</div></details>
<details><summary><strong>2. Methods – Modified Delphi Process  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Core group of 6 EoE experts reviewed guidelines, literature, drafted patient‑centered statements (pediatric, assessment, monitoring).  </li>
<li style="margin-left: 0px;">Systematic PubMed/Embase/Cochrane search: Jan 1 1993–Sep 21 2024; English only; excluded animal studies, reviews, conference papers.  </li>
<li style="margin-left: 0px;">21 additional adult/pediatric experts voted online (scale 1‑9); ≥80 % scoring 7‑9 accepted.  </li>
<li style="margin-left: 0px;">First round: 27/28 statements met threshold; one revised and approved after virtual discussion (second round).  </li>
</ul>
</div></details>
<details><summary><strong>3. Pediatric Considerations – Consensus Statements 1–4  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Indications for Endoscopy in Infants ≤18 months  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform endoscopy when chronic feeding difficulties, failure to advance textures, malnutrition, or poor weight gain are present.  </li>
<li style="margin-left: 0px;">High clinical suspicion needed; infants cannot self‑report dysphagia or pain.  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Indications for Endoscopy in Children &gt;18 months  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Consider endoscopy for protracted vomiting/reflux, abdominal pain, failure of feeding therapy, dysphagia, or food impaction.  </li>
<li style="margin-left: 0px;">Symptoms markedly affect quality of life; early diagnosis prevents strictures and growth failure.  </li>
</ul>
</div></details>
<details><summary><strong>3.3 General High‑Risk Indicators (any age)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopy warranted with high suspicion based on esophageal symptoms <strong>plus</strong> atopic comorbidities or family history of atopy/EoE.  </li>
<li style="margin-left: 0px;">≈80 % of EoE patients have atopic disorders (asthma, allergic rhinitis, eczema, food allergy).  </li>
</ul>
</div></details>
<details><summary><strong>3.4 Biopsy Protocol in Suspected Pediatric EoE  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Obtain esophageal, gastric, and duodenal biopsies.  </li>
<li style="margin-left: 0px;">Minimum <strong>6 esophageal specimens</strong> from ≥2 levels (proximal &amp; distal) to capture patchy eosinophilia.  </li>
<li style="margin-left: 0px;">Gastric/duodenal samples sufficient to evaluate EGIDs, celiac disease, H pylori, autoimmune enteropathy.  </li>
</ul>
</div></details>
<details><summary><strong>3.5 Monitoring Biopsies in Known Pediatric EoE (Statement 5)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">During surveillance endoscopies, limit biopsies to the esophagus <strong>if</strong> prior gastric/duodenal samples were normal, current stomach/duodenum appear endoscopically normal, and no new upper‑GI symptoms exist.  </li>
</ul>
</div></details>
<details><summary><strong>3.6 Documentation of Endoscopic Severity (Statement 6)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Record <strong>EREFS</strong> (Edema, Rings, Exudates, Furrows, Strictures) at every pediatric procedure to enable baseline &amp; longitudinal severity assessment.  </li>
</ul>
</div></details>
<details><summary><strong>3.7 Role of Less‑Invasive Monitoring Tools (Statement 7)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Reserve esophageal string testing and unsedated transnasal endoscopy (uTNE) for <strong>monitoring</strong> disease status only; do not use them for initial EoE diagnosis.  </li>
</ul>
</div></details>
<details><summary><strong>3.8 Indications for Esophageal Dilation in Children (Statement 8)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Consider dilation in patients with symptomatic strictures or narrow‑caliber esophagus identified on esophagram/endoscopy, irrespective of current inflammatory activity.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Disease Assessment – Consensus Statements 13–22  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Initial Diagnostic Endoscopy Off Treatment (Statement 13)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform the first EGD <strong>off</strong> any therapy that could mask eosinophilic inflammation (PPIs, steroids, elimination diets).  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Comprehensive Standard EGD for Suspected EoE (Statement 14)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conduct a standard EGD allowing full assessment (including gastric/duodenal biopsies when indicated) and dilation of symptomatic strictures if needed.  </li>
</ul>
</div></details>
<details><summary><strong>4.3 Mandatory Esophageal Biopsies in All Relevant Cases (Statement 15)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Obtain esophageal biopsy specimens <strong>whenever</strong> symptoms or endoscopic findings suggest EoE, regardless of age.  </li>
</ul>
</div></details>
<details><summary><strong>4.4 Functional Luminal Imaging Planimetry (FLIP) – Current Role (Statement 16)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Routine use of functional luminal imaging planimetry in EoE care remains undetermined; not recommended for all patients presently.  </li>
</ul>
</div></details>
<details><summary><strong>4.5 Integrated Disease Activity Assessment (Statements 17‑20)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Assess disease activity by jointly considering <strong>symptoms</strong>, endoscopic findings (EREFS), and histologic features (peak eosinophil count + other markers).  </li>
<li style="margin-left: 0px;">In adults, maintain high suspicion for strictures; endoscopic detection of narrowing is <strong>not</strong> sensitive.  </li>
</ul>
</div></details>
<details><summary><strong>4.6 Techniques to Measure Esophageal Diameter (Statement 22)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Esophageal caliber can be evaluated via esophagography, FLIP, or “sizing” with balloon/bougie dilators.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Disease Monitoring – Consensus Statements 23–28  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Treatment‑Specific Monitoring Intervals (Statement 23)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Diet elimination: repeat assessment <strong>6‑8 weeks</strong> after initiation.  </li>
<li style="margin-left: 0px;">PPIs &amp; topical steroids: reassess <strong>8‑12 weeks</strong> post‑start.  </li>
<li style="margin-left: 0px;">Biologics: initial evaluation up to <strong>24 weeks</strong>; earlier checks allowed for severe disease or frequent dilation needs.  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Biopsy Protocol During Monitoring Endoscopies (Statement 24)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Use identical protocol as diagnostic EGD: ≥6 esophageal biopsies from ≥2 levels.  </li>
</ul>
</div></details>
<details><summary><strong>5.3 Washout Considerations After Therapy Change (Statement 25)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Schedule monitoring endoscopy after sufficient wash‑out of prior treatment to isolate efficacy of the new regimen.  </li>
</ul>
</div></details>
<details><summary><strong>5.4 Use of Less‑Invasive Modalities for Monitoring (Statements 26‑27)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">uTNE, esophageal string test (EST), sponge/balloon devices may be employed <strong>if</strong> expertise &amp; availability permit, but <strong>not</strong> when dilation is required or for initial diagnosis.  </li>
</ul>
</div></details>
<details><summary><strong>5.5 Structured Clinical &amp; Endoscopic Follow‑Up (Statement 28)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Implement organized monitoring programs to prevent gaps in care that heighten fibrostenotic risk.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Pediatric Therapeutic &amp; Procedural Guidance (Statements 5–11)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Statement 5</strong>: If prior gastric/duodenal biopsies were normal and no new GI symptoms arise, monitoring endoscopies may sample the esophagus <strong>only</strong>, reducing unnecessary risk, cost, anesthesia time.  </li>
<li style="margin-left: 0px;"><strong>Statement 6</strong>: Document <strong>EREFS</strong> in all children with suspected or known EoE to permit initial &amp; longitudinal severity scoring (total score 0‑9).  </li>
<li style="margin-left: 0px;"><strong>Statement 7</strong>: Assess readiness &amp; preprocedure anxiety in older adolescents/young adults; address needle phobia with numbing cream, inhalation induction, or uTNE.  </li>
<li style="margin-left: 0px;"><strong>Statement 8</strong>: Implement a structured transition plan from pediatric to adult care; 100 % of voters agreed on necessity for proactive hand‑off.  </li>
</ul>
</div></details>
<details><summary><strong>7. Disease Assessment – Endoscopic &amp; Histologic Framework (Statements 13‑22)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Off‑Treatment Diagnostic EGD (Statement 13)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Initial EGD must be performed <strong>off</strong> any therapy that could suppress eosinophilic inflammation (e.g., PPIs, elimination diets).  </li>
</ul>
</div></details>
<details><summary><strong>7.2 Comprehensive Standard EGD (Statement 14)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Include gastric/duodenal biopsies when indicated; dilate symptomatic strictures during the same session if needed.  </li>
</ul>
</div></details>
<details><summary><strong>7.3 Universal Esophageal Biopsy Requirement (Statement 15)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">All patients with compatible symptoms or endoscopic signs must have esophageal biopsies obtained for definitive diagnosis &amp; longitudinal monitoring.  </li>
</ul>
</div></details>
<details><summary><strong>7.4 Histologic Scoring Beyond Peak Eosinophil Count (Statements 16‑20)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Peak eosinophil count interpreted alongside lamina propria fibrosis, basal zone hyperplasia, and other histologic features; incorporated in <strong>I‑SEE</strong> severity index.  </li>
<li style="margin-left: 0px;">Symptoms of dysphagia must be evaluated with context of food avoidance, behavioral modifications, and prior dilation status.  </li>
</ul>
</div></details>
<details><summary><strong>7.5 Stricture Suspicion &amp; Detection Sensitivity (Statements 20‑22)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adult endoscopists should maintain high suspicion for strictures; detection sensitivity low (≈33 % for ≤13 mm rings vs. esophagram).  </li>
<li style="margin-left: 0px;">Esophageal diameter measurable by barium swallow, FLIP, or “sizing” with balloon/bougie dilators.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Disease Monitoring – Consensus Statements 23–28  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 Treatment‑Based Monitoring Intervals (Statement 23)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Diet elimination: reassess at <strong>6‑8 weeks</strong>.  </li>
<li style="margin-left: 0px;">PPIs &amp; topical steroids: repeat evaluation <strong>8‑12 weeks</strong> after start.  </li>
<li style="margin-left: 0px;">Biologics: initial monitoring up to <strong>24 weeks</strong>; earlier checks allowed for severe disease or rapid symptom change.  </li>
</ul>
</div></details>
<details><summary><strong>8.2 Consistent Biopsy Strategy During Surveillance (Statement 24)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Same protocol as diagnostic EGD: ≥6 esophageal biopsies from ≥2 distinct levels, targeting active furrows/exudates when present.  </li>
</ul>
</div></details>
<details><summary><strong>8.3 Wash‑out Timing After Therapy Change (Statement 25)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Interval must allow complete washout of prior agent (PPIs ≥1–2 months; steroids ≈90‑120 days; dupilumab 4‑6 months due to long half‑life).  </li>
</ul>
</div></details>
<details><summary><strong>8.4 Role of Less‑Invasive Monitoring Tools (Statements 26‑27)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">uTNE, string test, sponge/balloon devices <strong>can</strong> be considered for disease activity assessment if dilation is not anticipated and local expertise exists.  </li>
<li style="margin-left: 0px;">These modalities <strong>must not</strong> replace sedated upper endoscopy when strictures are present or initial diagnosis is required.  </li>
</ul>
</div></details>
<details><summary><strong>8.5 Structured Clinical &amp; Endoscopic Surveillance (Statement 28)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adopt organized monitoring programs to avoid care gaps that accelerate fibrostenosis; combine clinic evaluation with intermittent endoscopic reassessment.  </li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
